476 related articles for article (PubMed ID: 28167778)
1. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics.
Dahlman JE; Kauffman KJ; Xing Y; Shaw TE; Mir FF; Dlott CC; Langer R; Anderson DG; Wang ET
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2060-2065. PubMed ID: 28167778
[TBL] [Abstract][Full Text] [Related]
2. A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation.
Paunovska K; Sago CD; Monaco CM; Hudson WH; Castro MG; Rudoltz TG; Kalathoor S; Vanover DA; Santangelo PJ; Ahmed R; Bryksin AV; Dahlman JE
Nano Lett; 2018 Mar; 18(3):2148-2157. PubMed ID: 29489381
[TBL] [Abstract][Full Text] [Related]
3. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening.
Guimaraes PPG; Zhang R; Spektor R; Tan M; Chung A; Billingsley MM; El-Mayta R; Riley RS; Wang L; Wilson JM; Mitchell MJ
J Control Release; 2019 Dec; 316():404-417. PubMed ID: 31678653
[TBL] [Abstract][Full Text] [Related]
4. Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.
Lee TJ; Haque F; Vieweger M; Yoo JY; Kaur B; Guo P; Croce CM
Methods Mol Biol; 2015; 1297():137-52. PubMed ID: 25896001
[TBL] [Abstract][Full Text] [Related]
5. Peptides for nucleic acid delivery.
Lehto T; Ezzat K; Wood MJA; El Andaloussi S
Adv Drug Deliv Rev; 2016 Nov; 106(Pt A):172-182. PubMed ID: 27349594
[TBL] [Abstract][Full Text] [Related]
6. Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo.
Sago CD; Lokugamage MP; Lando GN; Djeddar N; Shah NN; Syed C; Bryksin AV; Dahlman JE
Nano Lett; 2018 Dec; 18(12):7590-7600. PubMed ID: 30216729
[TBL] [Abstract][Full Text] [Related]
7. Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery.
Paunovska K; Gil CJ; Lokugamage MP; Sago CD; Sato M; Lando GN; Gamboa Castro M; Bryksin AV; Dahlman JE
ACS Nano; 2018 Aug; 12(8):8341-8349. PubMed ID: 30016076
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases.
Fattal E; Fay F
Adv Drug Deliv Rev; 2021 Aug; 175():113809. PubMed ID: 34033819
[TBL] [Abstract][Full Text] [Related]
9. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
10. High-throughput evaluation of polymeric nanoparticles for tissue-targeted gene expression using barcoded plasmid DNA.
Kim J; Vaughan HJ; Zamboni CG; Sunshine JC; Green JJ
J Control Release; 2021 Sep; 337():105-116. PubMed ID: 34097924
[TBL] [Abstract][Full Text] [Related]
11. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery.
Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK
J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899
[TBL] [Abstract][Full Text] [Related]
12. N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver.
Wang HX; Xiong MH; Wang YC; Zhu J; Wang J
J Control Release; 2013 Mar; 166(2):106-14. PubMed ID: 23266452
[TBL] [Abstract][Full Text] [Related]
13. Non-viral nucleic acid containing nanoparticles as cancer therapeutics.
Kozielski KL; Rui Y; Green JJ
Expert Opin Drug Deliv; 2016 Oct; 13(10):1475-87. PubMed ID: 27248202
[TBL] [Abstract][Full Text] [Related]
14. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
Iyer AK; Duan Z; Amiji MM
Mol Pharm; 2014 Aug; 11(8):2511-26. PubMed ID: 24661041
[TBL] [Abstract][Full Text] [Related]
15. [Drug Delivery to Various Body Organs via Non-blood Circulatory Pathway].
Kogure K; Fukuta T
Yakugaku Zasshi; 2020; 140(5):611-615. PubMed ID: 32378660
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
Bartlett DW; Davis ME
Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
[TBL] [Abstract][Full Text] [Related]
17. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
18. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I.
Kim SI; Shin D; Choi TH; Lee JC; Cheon GJ; Kim KY; Park M; Kim M
Mol Ther; 2007 Jun; 15(6):1145-52. PubMed ID: 17440441
[TBL] [Abstract][Full Text] [Related]
19. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.
Xu L; Anchordoquy T
J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
